Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 41.46 percent increase over losses of $(0.41) per share from the same period last year. The company reported quarterly sales of $1.154 million which missed the analyst consensus estimate of $1.295 million by 10.90 percent. This is a 3.50 percent increase over sales of $1.115 million the same period last year.